ChartSpan Acquires Personal Health Data Platform Validic to Scale Remote Patient Monitoring
ChartSpanAcquirer
ValidicTarget
ChartSpan has completed the acquisition of health‑data platform Validic, with terms undisclosed, backed by financing from BIP Capital, to broaden its remote patient monitoring (RPM) capabilities.
ChartSpan has completed the acquisition of Validic, with financial terms not disclosed, marking a strategic expansion of its remote patient monitoring (RPM) platform. The deal, announced on June 22, 2026, was financed by institutional investors led by BIP Capital and brings together ChartSpan’s full‑service clinical care teams with Validic’s IoT‑enabled health data infrastructure.
Deal Terms
The transaction closes the gap between care‑management software and device‑level data collection. While the purchase price remains private, the integration will see Validic’s normalized API—supporting more than 700 consumer and clinical‑grade devices and covering roughly 20 million connected lives—embedded directly into ChartSpan’s existing chronic‑care and advanced primary‑care workflows. The combined entity will operate under the ChartSpan brand, leveraging the unified delivery layer to serve health systems, payers, digital‑health innovators, and life‑science firms.
Strategic Rationale
ChartSpan’s core offering has historically centered on Chronic Care Management (CCM) and Advanced Primary Care Management (APCM), which rely on periodic outreach. By adding Validic’s continuous biometric streams, the company can shift from episodic check‑ins to real‑time clinical triage, alerting care managers to early signs of decompensation before emergencies arise. The unified platform also promises frictionless data flow into major EHRs such as Epic and Oracle Health, reducing integration overhead for providers. Executives from both firms highlighted the convergence of full‑service care orchestration with automated RPM as a response to the persistent data blind spot that hampers value‑based care contracts.
The acquisition expands ChartSpan’s addressable market beyond ambulatory provider groups. With direct access to a robust device‑logistics network and a developer‑friendly API, the company can now target payer‑led population health programs, support real‑world evidence collection for pharma, and supply a reliable backend for emerging digital‑health applications. Validic’s CEO, Drew Schiller, noted that the partnership bridges the gap between home‑generated health signals and clinical execution, positioning the combined firm to capture a larger share of the rapidly growing RPM and health‑data integration market.
Why It Matters
For ChartSpan, the deal eliminates the need to build a device‑integration layer from scratch, accelerating its move into enterprise‑scale RPM and opening new revenue streams with payers and life‑science partners. Competitors that continue to offer siloed care‑management tools may find it harder to meet the data‑intensity demanded by value‑based contracts, potentially ceding market share to the integrated solution.
Validic gains immediate access to ChartSpan’s extensive clinical workforce and established payer relationships, giving its API a broader commercial runway. The combined platform also raises the bar for other health‑data aggregators, who will now need to demonstrate comparable device breadth and seamless EHR integration to stay relevant in a market that increasingly rewards end‑to‑end solutions.
Key Points
- ChartSpan completed the acquisition of Validic on June 22, 2026; deal value was not disclosed
- Financing for the transaction was led by BIP Capital
- Validic’s API supports over 700 devices and connects roughly 20 million lives
- The combined entity will integrate continuous biometric data into ChartSpan’s CCM and APCM programs
- The acquisition expands ChartSpan’s target market to include payers, life‑science firms, and digital‑health innovators
Analysis
The ChartSpan‑Validic deal underscores a broader shift in health‑tech SaaS toward unified data pipelines that combine clinical workflow with real‑time device streams. While the purchase price remains private, the integration eliminates a costly, time‑intensive build‑out for device normalization, allowing ChartSpan to capture higher gross margins on its RPM services. For investors, the transaction highlights the premium placed on platforms that can deliver end‑to‑end value‑based care solutions, suggesting that future valuations in the remote monitoring space will increasingly factor in device ecosystem breadth and API scalability. Operators can expect pressure to adopt similar integrated models to stay competitive, as payers and health systems prioritize continuous, actionable data over periodic outreach. The move also signals to venture capitalists that capital will flow toward companies that can bridge the gap between consumer health wearables and enterprise clinical operations, accelerating consolidation in the health‑data SaaS vertical.